Efficacy of voglibose added to alogliptin in Japanese patients with diabetes mellitus

Efficacy of voglibose added to alogliptin in Japanese patients with diabetes mellitus - Efficacy of voglibose added to alogliptin in diabetic patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009516

Enrollment

180

Registered

2012-12-31

Start date

2013-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Interventions

0.6 mg per day of voglibose with alogliptin 0.2 mg per day of voglibose with alogliptin alogliptin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Japanese patients who are treated with alogliptin for type 2 diabetes mellitus

Exclusion criteria

Exclusion criteria: contraindication of voglibose

Design outcomes

Primary

Measure	Time frame
HbA1c, 1,5-AG, glycoalbumin	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026